**EWG CRITERIA**
- developing country impact
- financial aspects
- operational efficiencies

**FINAL SELECTED PROPOSALS**

**Financing Mechanisms**
- A new indirect tax (a consumer based tax)
- Voluntary business and consumer contributions
- Taxation of repatriated pharmaceutical profits
- New donor funds for health R&D

**Funding Allocation Mechanisms**
- Funding via Product Development Partnerships (PDPs)
- Direct grants to small companies and grants for DC trials
- Milestone Prizes: Innocentive
- End-Prizes (cash): Rapid Diagnostic Test for TB
- Purchase or procurement agreements

**Efficiency Proposals**
- Regulatory harmonization (Dev Country-focused)
- Pre-competitive R&D platforms

**Four financing mechanisms** that will triple available funds for R&D for neglected diseases of the developing world

**Five funding allocation mechanisms** that the EWG believes will optimally allocate both existing funds and new funds raised by the four proposed financing mechanisms

**Two efficiency proposals** aimed at cutting R&D costs across the board